1116 An Institutional Review of Holmium LASER Enucleation of the Prostate Morbidity

Abstract

Abstract Aim To review morbidity rate of Holmium Laser Enucleation of Prostate (HoLEP) in at a single institution in the UK. Method A retrospective review of 148 patients who underwent HoLEP between 2017 and 2022 was performed. Demographic, intraoperative, immediate postoperative and postoperative follow up data were recorded to determine the incidence of complications. Mean data are presented. Results The mean age was 71.4 years (SD 7.5), prostate volume 109.7ml (SD 38.5), weight of enucleated tissue 61.4g (SD 41.4), and length of stay 1.5 days (SD 0.9). 76 patients (51.4%) had long term catheter and 18 patients (12.2%) had intermittent self-catheterization preoperatively. 114 patients (77%) had successful TWOC prior to discharge. 4 patients (2.7%) never had a successful TWOC. Clavien-Dindo II complications included urinary infection (2.8%, n = 4) and lavage for haematuria (2.7%, n = 4), and of those, clot retention in 1.4% (n = 2). Clavien-Dindo III complications included urethral stricture (1.4%, n = 2) and clot evacuation for hematuria (0.7%, n = 1). The 30-day readmission rate was 2.7 % (n = 4), all for clot retention. Among 5 patients (3.4%) with haematuria or clot retention, 4 patients were treated with lavage/irrigation, and 1 required bladder washout in theatre. There were 3 patients on anticoagulant medications and 1 patient on an antiplatelet within 30 days of HoLEP. Conclusions HoLEP is associated with low incidence of morbidity and low rate of readmission, however pre-operative anticoagulant use was associated with readmission due to haematuria.